Advanced development of ErbB family-targeted therapies in osteosarcoma treatment

• Published in: Investigational new drugs Vol. 37; no. 1; pp. 175 - 183
• Main Authors: Wang, Wei, Zhao, Hua-fu, Yao, Teng-fei, Gong, Hao
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2019; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Apoptosis; Biocompatibility; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Bone tumors; Breast cancer; Breast carcinoma; Chemotherapy; Cisplatin; Clinical trials; Diagnostic systems; Doxorubicin; Epidermal growth factor receptors; ErbB protein; ErbB Receptors - antagonists & inhibitors; ErbB-2 protein; Humans; Immunotherapy; Lung carcinoma; MAP kinase; Medical prognosis; Medical research; Medicine; Medicine & Public Health; Metastases; Metastasis; Methotrexate; Molecular Targeted Therapy; Monoclonal antibodies; Oncology; Osteosarcoma; Osteosarcoma - drug therapy; Osteosarcoma - metabolism; Osteosarcoma - pathology; Patients; Pharmacology/Toxicology; Prognosis; Radiation therapy; Review; Sarcoma; Solid tumors; Splicing; Surgery; Tumors; Metastasis; ErbB; Osteosarcoma; Immunotherapy

Summary Osteosarcoma (OS) is the most common primary aggressive and malignant bone tumor. Newly diagnostic OS patients benefit from the standard therapy including surgical resection plus radiotherapy and neoadjuvant chemotherapy (MAP chemotherapy: high-dose methotrexate, doxorubicin and cisplatin)....